Portland Veterinary Specialists and IDEXX Laboratories
Canine Lymphoma SDMA Study
Portland Veterinary Specialists in conjunction with IDEXX Laboratories is pleased to offer the opportunity for clients to participate in a study designed to determine the association between lymphoma in dogs and increased symmetric dimethylarginine (SDMA).
Dogs of any age, breed or sex
Newly diagnosed with Stage 3 or greater multicentric lymphoma
Dogs will have been diagnosed with lymphoma by cytology (aspirate) or biopsy evaluated by a pathologist.
Dogs need to have a serum creatinine run prior to admission and be < 1.6 mg/dl
Dogs with cutaneous or gastrointestinal lymphoma
Dogs treated with corticosteroids or other chemotherapeutic or biologic agents for their lymphoma or other neoplastic diseases
Dogs with concurrent diseases (e.g., diabetes, CKD, CHF, neoplastic disease other than lymphoma, immune disorders, etc.)
Dogs with a serum creatinine of ≥ 1.6 mg/dL on presentation
Dogs currently being treated with any drugs (e.g., nonsteroidal anti-inflammatory drugs, antimicrobials, cardiac medications, insulin, diuretics, glucocorticoids.
Oral/topical heartworm preventatives
For this study, we will be covering the cost of all standard staging tests involved in diagnosis to include:
Urinalysis and Urine Protein Creatinine ratio
Lymph node cytology, PCR and flow cytometry for immunophenotyping
Thoracic radiographs (3 views)
Bone marrow aspirate cytology.
Glomerular Filtration Rate (GFR)
The pet owner will be financially responsible for the cost of the initial consultation examination, any additional testing that is recommended, and the cost of any chemotherapy.
Please direct any questions pertaining to this study or patient eligibility to:
Study Director: Jeffrey Philibert DVM DACVIM (Oncology) or Nikki Seeley LVT, VTS (Oncology)
Phone: (207) 780-0271; Email: firstname.lastname@example.org
Study Site: Portland Veterinary Specialists, 739 Warren Avenue, Portland ME 04103
AN EXCITING NEW WAY TO HELP
TREAT CANINE LYMPHOMA
Inspired by advances in human cancer treatment, a new monoclonal antibody (MAb) therapy is available for the treatment of lymphoma in dogs. Developed specifically for dogs with lymphoma, canine MAb therapy is an innovative treatment that’s designed to target and kill lymphoma cells. Portland Veterinary Specialists is now accepting patients for this new conditionally licensed therapy.
To learn more about MAb technology, visit www.aratana.com, or email Dr. Jeffrey Philibert at email@example.com.
Veterinarians, to enroll you patients, please call 207-780-0271.